Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Tikva Allocell

Tikva Allocell

Series AUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$8.0Msum of rounds with a disclosed amount only
Named investors
1
Financing history
1 rounds
  1. Jul 22, 2026
    Series A · $8.0M (disclosed)
    Kantharos Capital (lead) via Terence Tan
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors”
Investors on record
1 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Jul 22, 2026
    Tikva Allocell announced Series A of $8,000,000, led by Kantharos Capital
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company